TRAW – traws pharma, inc. (US:NASDAQ)
Stock Stats
News
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
Traws Pharma (NASDAQ:TRAW) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients [Yahoo! Finance]
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
Traws Pharma (NASDAQ:TRAW) was upgraded by analysts at Zacks Research to a "hold" rating.
Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Chernett Jorey
Form 8-K Traws Pharma, Inc. For: Jan 13
Form 8-K Traws Pharma, Inc. For: Dec 17
Form 4 Traws Pharma, Inc. For: Dec 12 Filed by: Leaman John Harold
Form 4 Traws Pharma, Inc. For: Dec 12 Filed by: Clarke Trafford
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.